about
Gene Therapy for Pediatric Cancer: State of the Art and Future PerspectivesFuture of adenoviruses in the gene therapy of arthritisReplication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2GammadeltaT cells initiate acute inflammation and injury in adenovirus-infected liver via cytokine-chemokine cross talk.Adenovirus vector designed for expression of toxic proteins.Calcium gluconate in phosphate buffered saline increases gene delivery with adenovirus type 5.Adenoviral vector-mediated gene therapy for gliomas: coming of age.Gene therapy for paediatric leukaemia.Current strategies and future directions for eluding adenoviral vector immunityHuman cytomegalovirus US2 causes similar effects on both major histocompatibility complex class I and II proteins in epithelial and glial cellsNovel molecular approaches to cystic fibrosis gene therapy.Ebola virus vaccines - reality or fiction?Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.Production of human epidermal growth factor using adenoviral based system.Hypomorphic sialidase expression decreases serum cholesterol by downregulation of VLDL production in mice.Comparative sequence analysis of the largest E1A proteins of human and simian adenoviruses.Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1.Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.Development of an Ad7 cosmid system and generation of an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus.HER3 targeting of adenovirus by fiber modification increases infection of breast cancer cells in vitro, but not following intratumoral injection in mice.Functional expression of thymidine kinase in human leukaemic and colorectal cells, delivered as EGFP fusion protein by herpesvirus saimiri-based vector.In vivo episomal maintenance of a herpesvirus saimiri-based gene delivery vector.
P2860
Q24792778-01B901F7-33C2-41D6-9D8B-320591ACD9EDQ24805400-A88E952A-B6E3-4B41-B98A-37AC3B93FD8DQ27487570-BC8A9F5A-4417-407C-AAE8-B296F74C1E87Q30439944-B96FE31B-14B0-4125-B793-AC4A55AD237BQ30719733-2784424D-A5D5-4796-8203-E849D0509A4EQ33711997-AB702065-3699-4817-A475-9AE4B8988CFBQ34022048-1C8B4427-5F8A-4994-AB57-42933F715193Q34451905-510FE19B-2C2C-44F3-8D8C-3C9F8C54C093Q34585554-21EBE9E8-D633-489E-89BD-B7AA5A37AA36Q35803399-BFC3C2FE-F48F-47C7-B6B6-C81FEE79FD40Q36012920-D39F1FF2-BD6E-4144-A8AA-FBA88C7E435AQ38881265-A934232F-7AF1-460E-B9F3-7055E6F68B5BQ38893420-E59662D2-1C67-40BA-B870-B1D557B09813Q39068847-3B1564A6-E946-44E5-94C5-72A510B8ADE6Q39277489-18FABDA7-22A4-442A-9E54-F6E843F69DDBQ39753100-26584D12-F4CB-4EE1-A2DA-AAC19E6BEFAFQ40516862-8398CFF0-16F7-463F-8CE0-B6D9976F88A1Q40665345-6B80AD54-ED04-45B2-896E-CC4DC606DA65Q40669254-1BBED112-2256-490D-A448-725A78AE003EQ42288961-5273F957-B309-45AC-9D93-06DB1CC283CAQ44970732-8D0976B9-A2CD-4229-AB40-F35FEA063C6AQ45882772-06F49911-F2AF-4E8C-9DAD-6DB487705E70
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Adenovirus vectors for human gene therapy.
@ast
Adenovirus vectors for human gene therapy.
@en
Adenovirus vectors for human gene therapy.
@nl
type
label
Adenovirus vectors for human gene therapy.
@ast
Adenovirus vectors for human gene therapy.
@en
Adenovirus vectors for human gene therapy.
@nl
prefLabel
Adenovirus vectors for human gene therapy.
@ast
Adenovirus vectors for human gene therapy.
@en
Adenovirus vectors for human gene therapy.
@nl
P1476
Adenovirus vectors for human gene therapy.
@en
P2093
P304
P356
10.1016/S0065-3527(00)55014-3
P577
2000-01-01T00:00:00Z